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Risk of Major Adverse Cardiovascular Events and Major Hemorrhage
Among White and Black Patients Undergoing Percutaneous Coronary
Intervention
Anping Cai, MD, PhD; Chrisly Dillon, MD; William B. Hillegass, MD, PhD; Mark Beasley, PhD; Brigitta C. Brott, MD; Vera A. Bittner, MD,
MSPH; Gilbert J. Perry, MD; Ganesh V. Halade, PhD; Sumanth D. Prabhu, MD; Nita A. Limdi, PharmD, PhD, MSPH
Background-—Data on racial disparities in major adverse cardiovascular events (MACE) and major hemorrhage (HEM) after
percutaneous coronary intervention are limited. Factors contributing to these disparities are unknown.
Methods and Results-—PRiME-GGAT (Pharmacogenomic Resource to Improve Medication Effectiveness–Genotype-Guided
Antiplatelet Therapy) is a prospective cohort. Patients aged ≥18 years undergoing percutaneous coronary intervention were
enrolled and followed for up to 1 year. Racial disparities in risk of MACE and HEM were assessed using an incident rate ratio.
Sequential cumulative adjustment analyses were performed to identify factors contributing to these disparities. Data from 919
patients were included in the analysis. Compared with white patients, black patients (n=203; 22.1% of the cohort) were younger
and were more likely to be female, to be a smoker, and to have higher body mass index, lower socioeconomic status, higher
prevalence of diabetes mellitus and moderate to severe chronic kidney disease, and presentation with acute coronary syndrome
and to undergo urgent percutaneous coronary intervention. The incident rates of MACE (34.1% versus 18.2% per 100 person-years,
P<0.001) and HEM (17.7% versus 10.3% per 100 person-years, P=0.02) were higher in black patients. The incident rate ratio was
1.9 (95% CI, 1.3–2.6; P<0.001) for MACE and 1.7 (95% CI, 1.1–2. 7; P=0.02) for HEM. After adjustment for nonclinical and clinical
factors, black race was not significantly associated with outcomes. Rather, differences in socioeconomic status, comorbidities, and
coronary heart disease severity were attributed to racial disparities in outcomes.
Conclusions-—Despite receiving similar treatment, racial disparities in MACE and HEM still exist. Opportunities exist to narrow
these disparities by mitigating the identified contributors. ( J Am Heart Assoc. 2019;8:e012874. DOI: 10.1161/JAHA.119.
012874.)
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C oronary heart disease (CHD) is a leading cause ofmorbidity, mortality, and medical costs in the United
States.1 Although the prevalence of CHD is similar for black
and white people,2 cardiovascular events, rehospitalization,
and mortality are disproportionately higher for black
patients.3–8
Percutaneous coronary intervention (PCI) is an important
therapeutic approach for CHD patients, especially those with
an acute coronary syndrome (ACS).9–11 However, multiple
reports have shown that black patients have a higher risk of
cardiovascular events after PCI than white patients, with
studies attributing these differences to higher prevalence of
cardiovascular comorbidities,12 lower socioeconomic status
(SES),13 and different treatment received during hospitaliza-
tion of black patients.14
Given changing demographics, increasing minority groups
including blacks, and the disproportionate CHD burden among
black people, understanding differences in outcomes and
elucidating reasons for the differences will facilitate the
development of race-specific interventions and eventually
reduce race-related disparities.
In this study, in patients undergoing PCI, we assess
whether the risk of major adverse cardiovascular events
(MACE) and major hemorrhage (HEM) differs by race,
identify factors related to MACE and HEM, and determine
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whether these factors contribute to the racial disparities in
outcomes.
Methods
Because of the sensitive nature of the data collected for this
study, requests to access the data set from qualified
researchers trained in human subject confidentiality protocols
may be sent to the corresponding author.
Study Design and Participant Enrollment
PRiME-GGAT (Pharmacogenomic Resource to Improve Medi-
cation Effectiveness–Genotype-Guided Antiplatelet Therapy)
is a prospective cohort study conducted under the approval of
the institutional review board of the University of Alabama at
Birmingham (UAB). Patients who were aged ≥18 years
undergoing PCI at the UAB Hospital were enrolled after
written informed consent was obtained.
Data Collection
Baseline characteristics
At baseline, patients were asked to identify their race and
ethnicity. During the index PCI, a structured case report form
was used to record patient demographics (age and sex),
lifestyle (eg, smoking), and SES (annual income, education
attainment, and health insurance), cardiovascular risk factors,
and comorbidities. Serum creatinine at admission was used to
calculate estimated glomerular filtration rate using the
Modification of Diet in Renal Disease formula.15
Patient characteristics at time of PCI
Vital signs (eg, blood pressure and heart rate) at time of PCI,
PCI status (urgent or elective), indication for PCI, access site,
coronary artery lesion location, periprocedural antiplatelet
use, contrast volume, number of coronary arteries with ≥70%
stenosis, and number and type of stents implanted were
documented.
Follow-Up and Studied Outcomes
Patients were followed for up to 1 year. Medical records
were reviewed, and changes in medication use, laboratory
parameters, any hospitalization, MACE, and HEM during
follow-up were documented. This approach ensured follow-
up for all patients, including patient encounters outside the
UAB Health System. Specifically, we requested physical
and/or electronic medical records from patients’ primary
care physicians and cardiologists and/or hospital records in
case of hospitalization. The laboratory parameters and
medication changes for every encounter were collected.
MACE outcomes were defined as a composite of all-cause
mortality, nonfatal myocardial infarction (MI), nonfatal
ischemic stroke, transient ischemic attack, and stent
thrombosis. Specifically, MI diagnosis was based on increase
of cardiac troponin with at least 1 value above the 99th
percentile upper reference limit plus ischemic symptoms
and/or new or presumed new ST-segment T-wave changes
or new left bundle-branch block16; if a case with stent
thrombosis was subsequently complicated by MI, we defined
the event as stent thrombosis. HEM outcomes were defined
as a composite of intracranial hemorrhage and/or gastroin-
testinal and other hemorrhage (eg, HEM related to access
site, genital urinary tract HEM) that causes substantial
hemodynamic compromise requiring treatment based on the
Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Arteries (GUSTO) criteria.17 MACE
and HEM outcomes were adjudicated by independent
cardiologists.
Statistical Analysis
ANOVA was used to assess differences for continuous
variables, and the v2 test was used for categorical variables
by race.
Incidence rates of MACE and HEM were calculated by
dividing the number of events by person-years of follow-up
accrued, and then we calculated incidence rate ratios (IRRs)
for MACE and HEM for black and white patients. The influence
of race on MACE and HEM was assessed using time-to-event
analysis. Hazard ratios and 95% CIs for the adjusted Cox
proportional hazards models were determined using the
Clinical Perspective
What Is New?
• Despite receiving similar guideline-recommended treatment,
among patients undergoing percutaneous coronary inter-
vention, black patients experienced higher incidence of
major adverse cardiovascular events and major hemorrhage
than white patients.
• These racial disparities in outcomes were attenuated after
adjustment for nonclinical (socioeconomic status) and
clinical (comorbidities and coronary heart disease severity)
factors.
What Are the Clinical Implications?
• Black race is not an independent risk factor for adverse
cardiovascular outcomes in coronary heart disease patients
undergoing percutaneous coronary intervention.
• Multifaceted implementation strategies are needed to
attenuate racial disparities in outcome.
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counting process format, permitting evaluation of time-
dependent risk intervals instead of a single event time.18,19
This method allowed individuals to contribute >1 event for the
analysis and supported the inclusion of time-varying covari-
ates (eg, comedications). Variance estimates and CIs were
corrected for dependence of observation within patients with
>1 event.
For all unadjusted and adjusted analyses, white patients
served as the reference group. We evaluated the contribution
of each of the following domains to observed racial
differences in outcomes by sequential cumulative adjust-
ment, as described previously.20 Specifically, in the first step
(model 1), we adjusted for demographics (age and sex) and
body mass index (calculated by weight in kilograms divided
by height in square meters). In the second step (model 2),
we adjusted for demographics, body mass index, and SES
(annual income, educational attainment, and health insur-
ance). In the third step (model 3), we adjusted for the prior 2
domains plus comorbidities (smoking, hypertension, dyslipi-
demia, diabetes mellitus, atrial fibrillation, chronic kidney
disease stage ≥3b, heart failure, prior history of PCI,
coronary artery bypass grafting, and hemorrhage). In the
fourth step (model 4), we adjusted for the prior 3 domains
plus CHD severity (number of coronary arteries with ≥70%
stenosis and presentation with ACS). In the fifth step (model
5), we adjusted for the prior 4 domains plus interventions
received during index PCI (number of stents implanted and
femoral artery access). In the final step (model 6), we
adjusted for the prior 5 domains plus medication use at
follow-up (dual antiplatelet therapy [DAPT], statins, b-
blockers and angiotensin-converting enzyme inhibitors/an-
giotensin receptor blockers, oral anticoagulants, and proton
pump inhibitors). The order of the assessed domains reflects
the temporal relationships of these factors, adjusting first for
patient demographics, SES, and clinical characteristics
before admission, followed by treatment received during
index hospitalization, and finally medication treatment during
follow-up. All analyses were performed using SAS v9.4 (SAS
Institute), and a 2-sided P<0.05 was considered statistically
significant.
Results
Participant Enrollment
A total of 1024 participants were enrolled. Patients with self-
reported race other than black or white (n=15) and incom-
plete follow-up (n=90) were excluded. Specifically, among the
90 patients with incomplete follow-up, 24 (10.6%) were black
and 66 (8.4%) were white (P=0.32). Consequently, data from
919 participants (mean age: 62.011.9 years) were included
in these analyses.
Comparison of Baseline Characteristics by Race
Black participants (n=203) accounted for 22.1% of the cohort.
As presented in Table 1, compared with white participants,
black participants were younger andmore likely to be female, to
have higher body mass index and lower annual income and
education attainment, and to be uninsured or underinsured.
Black participants were alsomore likely to smoke (28.6% versus
21.6%, P=0.01) and to have diabetes mellitus (48.8% versus
40.4%, P=0.03) and chronic kidney disease stage ≥3b (16.7%
versus 12.3%, P<0.001). White participants were more likely to
have dyslipidemia (77.8% versus 69.0%, P=0.01), atrial fibrilla-
tion (13.4% versus 5.4%, P=0.002), and previous history of CHD
(64.3% versus 55.2%, P=0.02) and to have undergone revascu-
larization (PCI: 39.9% versus 31.0%, P=0.02; coronary artery
bypass grafting: 28.9% versus 17.2%, P=0.001). White partic-
ipants were more likely to be on aspirin therapy (72.3% versus
60.3%, P=0.002) and clopidogrel (32.3% versus 24.3%, P=0.04)
at admission. The use of prasugrel or ticagrelor, statins, b-
blockers, angiotensin-converting enzyme inhibitors/an-
giotensin receptor blockers, oral anticoagulants, and proton
pump inhibitors at admission was similar across race groups.
Comparison of PCI Periprocedural Characteristics
by Race
As shown in Table 2, compared with white participants, black
participants were more likely to present with ACS (86.2%
versus 76.8%, P<0.001), to undergo urgent PCI (71.4% versus
52.3%, P<0.001), and to receive prasugrel or ticagrelor
loading during index PCI (69.5% versus 56.3%, P=0.001).
There were no significant differences in access site, numbers
of coronary arteries with ≥70% stenosis and stents implanted,
proportion of drug-eluting stents implanted, and use of
glycoprotein IIb/IIIa receptor inhibitors across race groups.
Comparison of Medication Use at Discharge and
Follow-Up by Race
At discharge, the institution of guideline-recommended DAPT,
statins, b-blockers, and angiotensin-converting enzyme inhi-
bitors/angiotensin receptor blockers was similar in both race
groups (Table 3). By the end of follow-up, however, the use of
b-blockers was significantly lower among black than white
participants (49.3% versus 59.6%, P=0.009). In addition, white
participants were more likely to receive oral anticoagulants at
discharge (12.3% versus 6.4%, P=0.02) and at follow-up
(11.4% versus 6.4%, P=0.03).
Within each race group, compared withmedication prescribed
at discharge, medication adherence at the end of follow-up was
lower. The use of DAPT declined among black participants (98.5%
versus 86.3%, P=0.04) and white participants (99.9% versus
DOI: 10.1161/JAHA.119.012874 Journal of the American Heart Association 3
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Table 1. Baseline Characteristics Among Black and White Patients Undergoing PCI
Characteristic All (n=919) Black (n=203) White (n=716) P Value
Demographics
Age, y, meanSD 62.011.9 58.811.9 63.011.8 <0.001
Female, n (%) 260 (28.3) 85 (41.9) 175 (24.4) <0.001
BMI, kg/m2, meanSD 30.06.4 31.07.6 29.76.0 0.02
SES
Annual income <$50 000 517 (67.9) 144 (88.9) 373 (62.2) <0.001
High school or less 505 (56.2) 128 (65.6) 377 (53.6) 0.003
Insurance
Medicaid/no insurance 130 (14.7) 42 (21.8) 88 (12.7) 0.002
Private/Medicare 757 (85.3) 151 (78.2) 606 (87.3)
Comorbidities
Current smoker 213 (23.2) 58 (28.6) 155 (21.6) 0.01
Hypertension 785 (85.4) 180 (88.7) 605 (84.5) 0.14
Dyslipidemia 697 (75.8) 140 (69.0) 557 (77.8) 0.01
Diabetes mellitus 388 (42.2) 99 (48.8) 289 (40.4) 0.03
Atrial fibrillation 107 (11.6) 11 (5.4) 96 (13.4) 0.002
CHD 572 (62.2) 112 (55.2) 460 (64.3) 0.02
Heart failure 245 (26.7) 50 (24.6) 195 (27.2) 0.46
eGFR distribution
≥60 648 (70.5) 154 (75.9) 494 (69.0) <0.001
45 to <60 149 (16.2) 15 (7.4) 134 (18.7)
30 to <45 73 (7.9) 12 (5.9) 61 (8.5)
<30 49 (5.3) 22 (10.8) 27 (3.8)
Prior event history
MI 290 (31.6) 68 (33.5) 222 (31.0) 0.50
Stroke/TIA 125 (13.6) 33 (16.3) 92 (12.9) 0.21
Hemorrhage 125 (13.6) 30 (14.8) 95 (13.3) 0.58
PCI 349 (38.0) 63 (31.0) 286 (39.9) 0.02
CABG 242 (26.3) 35 (17.2) 207 (28.9) 0.001
Medications on admission
Antiplatelet
Aspirin 591 (69.6) 114 (60.3) 477 (72.3) 0.002
Clopidogrel 259 (30.5) 46 (24.3) 213 (32.3) 0.04
Prasugrel or ticagrelor 47 (5.5) 8 (4.2) 39 (5.9) 0.37
Statins 570 (62.0) 115 (56.7) 455 (63.6) 0.07
b-Blocker 515 (56.0) 106 (52.2) 409 (57.1) 0.21
ACEI/ARB 461 (50.2) 96 (47.3) 365 (51.0) 0.35
Proton pump inhibitor 341 (37.1) 71 (35.0) 270 (37.7) 0.48
Oral anticoagulants 77 (8.4) 12 (5.9) 65 (9.1) 0.15
Data are shown as n (%) except as noted. Data missing for annual income (n=157; black, n=41 [20.2%], and white, n=116 [16.2%]; P=0.19); education (n=21; black, n=8 [3.9%], and white,
n=13 [1.8%]; P=0.10); insurance (n=32; black, n=10 [4.9%], and white, n=22 [3.1%]; P=0.22). ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker;
BMI, body mass index; CABG, coronary artery bypass grafting; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate (in mL/min/1.73 m2); MI, myocardial infarction; PCI,
percutaneous coronary intervention; SES, socioeconomic status; TIA, transient ischemic attack.
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90.8%, P<0.001), as did the use of b-blockers (black: 84.7%
versus 49.3%, P<0.001; white: 85.1% versus 59.6%, P<0.001).
The decrease in adherence toDAPT andb-blocker therapy did not
differ by race (P=0.78 for DAPT; P=0.19 for b-blocker). The use of
statins, angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers, and proton pump inhibitors remained similar
across time points in both race groups.
Comparison of Incidence Rates of MACE and HEM
by Race
The average follow-up time was 0.80.3 year. As presented
in Table 4, compared with white participants, the incidence
rate of MACE for black participants was significantly higher
(34.1% versus 18.2% per 100 person-years; IRR: 1.9; 95% CI,
1.3–2.6), which was driven by differences in nonfatal MI
(20.7% versus 9.4% per 100 person-years; IRR: 2.2; 95% CI,
1.4–3.3). Black participants had numerically higher incidence
rates of all-cause mortality (7.9% versus 5.1% per 100 person-
years; IRR: 1. 6; 95% CI, 0.8–3.0) and nonfatal ischemic stroke
(4.3% versus 1.7% per 100 person-years; IRR: 2.5; 95% CI,
0.9–6.7) but without statistically significant difference.
Compared with white participants, black participants also
had a significantly higher incidence rate of HEM (17.7% versus
10.3% per 100 person-years; IRR: 1.7; 95% CI, 1.1–2.7), driven
by differences in gastrointestinal hemorrhage (11.0% versus
Table 2. Periprocedural Characteristics Among Black and White Patients Undergoing PCI
PCI Periprocedural Characteristic All (n=919) Black (n=203) White (n=716) P Value
Vital sign
SBP, mm Hg, meanSD 14223 14523 14124 <0.001
DBP, mm Hg, meanSD 8414 8814 8314 <0.001
HR, beats/min, meanSD 7418 7516 7419 0.32
Procedure characteristics
PCI precipitating condition
STEMI 190 (20.7) 48 (23.7) 142 (19.8) <0.001
Non-STEMI 276 (30.0) 86 (42.3) 190 (26.5)
Unstable angina 259 (28.2) 41 (20.2) 218 (30.5)
Stable angina 194 (21.1) 28 (13.8) 166 (23.2)
PCI status
Urgent 519 (56.5) 145 (71.4) 374 (52.3) <0.001
Elective 400 (43.5) 58 (28.6) 342 (47.8)
Femoral artery access 773 (84.1) 163 (80.3) 610 (85.2) 0.06
Coronary artery lesion location
Left main 50 (4.1) 5 (2.0) 45 (4.6) <0.001
Left anterior descending 444 (36.3) 78 (30.8) 366 (37.7)
Left circumflex 291 (23.8) 84 (33.2) 207 (21.3)
Right coronary artery 372 (30.4) 72 (28.5) 300 (30.9)
Graft 53 (4.3) 7 (2.8) 46 (4.7)
No. of coronary arteries ≥70% stenosis, meanSD 1.8 (1.2) 1.9 (1.3) 1.8 (1.1) 0.11
No. of stents, meanSD 1.2 (0.6) 1.3 (0.6) 1.2 (0.6) 0.38
Drug-eluting stent 826 (91.5) 171 (88.1) 655 (92.4) 0.10
Contrast, mL, meanSD 146 (66) 146 (71) 146 (65) 0.89
PCI periprocedural antiplatelet medication
Glycoprotein IIb/IIIa receptor inhibitors 161 (17.5) 37 (18.2) 124 (17.3) 0.76
Clopidogrel loading 372 (40.5) 89 (43.8) 283 (39.5) 0.27
Prasugrel or ticagrelor loading 544 (59.2) 141 (69.5) 403 (56.3) 0.001
Data are shown as n (%) except as noted. DBP indicates diastolic blood pressure; HR, heart rate; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment
–elevation myocardial infarction.
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4.1% per 100 person-years; IRR: 2.7; 95% CI, 1.5–5.0). Black
participants also had a higher incidence rate of other
hemorrhage but without a statistically significant difference
(6.7% versus 5.4% per 100 person-years; IRR: 1.2; 95% CI, 0.6–
2.4). Among other hemorrhage, 12 events (in 3 black patients
and 9 white patients) were related to the access site, with no
significant differences by race (black versus white: 1.8% versus
1.5% per 100 person-years; IRR: 1.2; 95% CI, 0.3–4.3).
Table 3. Medications Use at Discharge and Follow-Up Among Black and White Patients
All (n=919) Black (n=203) White (n=716) P Value
Medications at discharge
DAPT 915 (99.6) 200 (98.5) 715 (99.9) 0.97
Aspirin+clopidogrel 612 (66.6) 134 (66.0) 478 (66.8)
Aspirin+prasugrel or ticagrelor 303 (33.0) 66 (32.5) 237 (33.1)
Statins 839 (91.6) 188 (92.6) 651 (91.3) 0.55
b-Blocker 779 (85.0) 172 (84.7) 607 (85.1) 0.89
ACEI/ARB 624 (67.9) 139 (68.5) 485 (67.7) 0.85
Proton pump inhibitor 350 (38.1) 76 (37.4) 274 (38.3) 0.96
Oral anticoagulants 101 (11.0) 13 (6.4) 88 (12.3) 0.02
Medications at time of event or last follow-up
DAPT 821 (89.7) 175 (86.3) 646 (90.8) 0.89
Aspirin+clopidogrel 604 (66.0) 128 (63.1) 476 (66.9)
Aspirin+prasugrel or ticagrelor 217 (23.7) 47 (23.2) 170 (23.9)
Statins 833 (91.0) 185 (91.1) 648 (91.0) 0.96
b-Blocker 524 (57.3) 100 (49.3) 424 (59.6) 0.009
ACEI/ARB 610 (66.7) 134 (66.0) 476 (66.9) 0.82
Proton pump inhibitor 368 (40.2) 75 (36.9) 293 (41.1) 0.31
Oral anticoagulants 95 (10.3) 13 (6.4) 82 (11.4) 0.03
Data are shown as n (%). ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; DAPT, dual antiplatelet therapy.
Table 4. Incidence Rates of MACE and HEM at 1 Year After PCI (Per 100 Person-Years)
All Patients (n=919) Black (n=203) White (n=716) IRR (95% CI) P Value
Follow-up, y 756.9 164.3 592.6
Average follow-up, y 0.80.3 0.80.3 0.80.3 0.47
Event (n) Rate (%) Event (n) Rate (%) Event (n) Rate (%)
MACE 164 21.7 56 34.1 108 18.2 1.9 (1.3–2.6) <0.001
All-cause mortality 43 5.7 13 7.9 30 5.1 1.6 (0.8–3.0) 0.19
Nonfatal MI 90 11.9 34 20.7 56 9.4 2.2 (1.4–3.3) <0.001
Nonfatal ischemic stroke 17 2.2 7 4.3 10 1.7 2.5 (0.9–6.7) 0.07
TIA 8 1.1 1 0.6 7 1.2 0.5 (0.02–3.3) 0.60
Stent thrombosis 6 0.8 1 0.6 5 0.8 0.7 (0.03–5.2) 0.84
HEM 90 11.9 29 17.7 61 10.3 1.7 (1.1–2.7) 0.02
Gastrointestinal hemorrhage 42 5.5 18 11.0 24 4.1 2.7 (1.5–5.0) 0.002
Intracranial hemorrhage 5 0.7 0 0 5 0.8 0 (0–3.0) 0.29
Other hemorrhage 43 5.7 11 6.7 32 5.4 1.2 (0.6–2.4) 0.53
For MACE: 11 patients had 2 nonfatal MI events; 2 patients had 2 nonfatal ischemic stroke events; 1 patient had 2 TIA events. For HEM: 16 patients had 2 events and 1 patient had 4
events. HEM indicates major hemorrhage; IRR, incident rate ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA,
transient ischemic attack.
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Factors Contributing to Racial Disparities in
MACE and HEM
Compared with white participants, black participants had a 1.9-
fold higher risk ofMACE (hazard ratio: 1.86; 95%CI, 1.24–2.80).
Inclusion of demographics and body mass index did not
attenuate the race–MACE association (Figure A). Incorporation
of SES and comorbidities attenuated the race–MACE associ-
ation by 22% and 5%, respectively. After controlling for CHD
severity, the race–MACE association was attenuated by 26%.
Interventions received during index PCI and medication use at
follow-up had no further impact on race–MACE association.
These findings indicate that SES and CHD severity were the 2
key factors contributing to racial disparities in MACE.
Compared with white participants, black participants had a
1.7-fold higher risk of HEM (hazard ratio: 1.71; 95% CI, 1.01–
2.91; FigureB). Incorporation of SES attenuated the race–HEM
association by 76%. After controlling for comorbidities and
CHD severity, the race–MACE association was attenuated by
15% and 23%, respectively. These findings indicate that SES,
comorbidities, and CHD severity were the key factors
contributing to racial disparities in HEM.
Discussion
To our knowledge, this study is the first to compare post-PCI
risks of both MACE and HEM by race in a prospective inception
cohort. We found that black participants had a higher incidence
of MACE and HEM than white participants. However, these
differences were attenuated after adjustment for nonclinical
(SES) and clinical (comorbidities and CHD severity) factors.
These findings suggest that racial disparities in outcomes are
attributable to differences in nonclinical and clinical factors.
Factors Associated With Racial Disparities in
MACE
Racial disparities in MACE after PCI have been reported, and
the reasons for these disparities are diverse, including
differences in cardiovascular risk factors and 30-day revas-
cularization rates12; clinical, angiographic, and SES factors13;
and treatment received during hospitalization.14 Our current
analysis also demonstrates a higher 1-year risk of MACE
among black participants. Our approach is unique because we
incorporated the influence of factors across 6 domains:
demographics, SES, comorbidities, CHD severity, treatment
received during PCI, and medication use at follow-up. Our
results elucidate the role of SES and CHD severity in racial
disparities in MACE after PCI.
Prior studies suggest that widowhood or insurance
status13 and median household income21 are the key SES
factors for racial disparities in MACE after PCI. These studies
evaluated the influence of individual SES indicators on
outcomes. As done previously,20 we combined annual income,
educational attainment, and health insurance into 1 SES
domain because it is unlikely that a single SES indicator is
adequate for predicting cardiovascular risk.22 Concordant
with previous results, our study shows the importance of SES
in attenuating the unadjusted racial differences in outcomes.
SES may influence outcomes through several mechanisms
including greater disease burden and poor lifestyle or health
behaviors.22,23 Indeed, both our and prior studies show that
lower SES is more prevalent among black cohorts and is
associated with a greater prevalence of risk factors and
comorbidities.24,25 Understanding the complex interplay of
SES, lifestyle, and comorbidities is vital to developing
interventions to attenuate these disparities.22,23
Unlike prior reports,3,12,13 our study did not show a
significant influence of comorbidities on race–MACE associ-
ation. We hypothesize that the inclusion of the CHD severity
measure captures the joint pathological effects of multiple
long-standing comorbidities (eg, smoking and diabetes mel-
litus) on CHD progression. Investigators have incorporated
CHD severity using varying definitions, including number of
stenoses, length and location of lesions, presentation with
ACS, and undergoing urgent PCI.3,12,13,20,26 We included
number of coronary arteries with ≥70% stenosis and ACS
presentation as indicators of CHD severity because they can
directly reflect the burden of coronary lesions and associated
ischemic risk.27,28 Because this measure did not differ by
race, our results support attribution of racial disparity in
MACE to differences in ACS presentation. Prior studies also
have shown that black patients are more likely to present with
ACS and experience stent thrombosis and death after PCI.3,26
The reasons for these differences are probably multifactorial
and may be related to differences in SES (eg, insurance
status).
We did not observe a significant impact of treatment
received during PCI or medications used after discharge on
race–MACE association. Unlike prior studies, which focused
on medication use only during PCI hospitalization or at
discharge,8,29 we assessed the impact of adherence to
guideline-recommended medications in the PCI periprocedu-
ral period, at discharge, and during follow-up regarding racial
disparities in outcomes. These results suggest that racial
disparities in outcomes due to differences in treatment
received can be attenuated with implementation of similar
treatment protocols.
Factors Associated With Racial Disparities in HEM
Our study shows that black patients have a higher risk of HEM
for up to 1 year after PCI. Although increased bleeding risk in
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black patients receiving fibrinolysis is well documented,30–33
the data on bleeding risk after PCI for black and white
patients are limited. To our knowledge, only 1 study has
specifically addressed racial disparities in bleeding and
mortality after PCI. Mehta et al reported that black patients
receiving primary PCI or fibrinolysis for ST-segment–elevation
MI had a higher in-hospital major bleeding risk than white
patients over the 3-day hospital stay.34 These findings
Figure. Factors influencing racial disparities in major adverse cardiovascular events (A) and in major
hemorrhage (B). Hazard ratios (HRs) are provided with 95% CIs. The vertical line indicates the reference
value of 1. In all models, values for black patients are compared with white patients. BMI indicates body
mass index; CHD, coronary heart disease; HEM, major hemorrhage; MACE, major adverse cardiovascular
events; PCI, percutaneous coronary intervention.
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collectively indicate that black patients are vulnerable with
either reperfusion strategy. Our study elucidates the influence
of (and interplay among) SES, comorbidity, and CHD severity
in explaining racial disparities in HEM. Lower SES was
associated with higher bleeding risk in another PCI study35
and among atrial fibrillation patients on warfarin therapy.36
We recognize that higher prevalence of diabetes mellitus and
moderate and severe chronic kidney disease among black
patients may also explain the higher incidence of HEM
observed in our study.37,38 Periprocedural bleeding complica-
tions following PCI are common in patients presenting with
ACS.39,40 Administration of more potent P2Y12 inhibitors
(prasugrel or ticagrelor loading during index PCI) may be
associated with increased risk of bleeding.41,42 In our study,
black participants were more likely to present with ACS and to
receive prasugrel or ticagrelor loading during index PCI.
However, at discharge and during follow-up, the use of
prasugrel or ticagrelor was similar across races, as was the
use of proton pump inhibitors. This result suggests that the
higher risk of HEM in black patients is independent of DAPT.
How other factors (eg, uncontrolled hypertension43 or
CYP2C19 genotype44) contribute to racial differences in
HEM was not assessed in this study, and we recognize this
limitation.
The strengths of this study are the prospective design and
the documentation of both clinical and nonclinical factors. The
medical records of all participants presenting to other
hospitals were obtained, reviewed, and adjudicated, enhanc-
ing capture of events and medication changes. We recognize
that despite the data-curation efforts, unmeasured factors
could have led to residual confounding. These factors include
severity of comorbid conditions (eg, uncontrolled hyperten-
sion), genetics,45 neighborhood effects,46 and inflammatory
burden,47 among others. We have not measured mental
illness (eg, depression), which can influence outcomes in
patients with CHD.48,49 Moreover, SES is a complex construct
including assessment of income, education, employment, and
social support (eg, marital status).50 We recognize these
limitations.
Conclusions
Despite receiving similar guideline-recommended treatment,
black patients undergoing PCI experienced higher incidences
of MACE and HEM than their white counterparts. The
reasons for these differences are multifactorial. Our results
highlight the contributions of SES and CHD severity to race–
MACE association and of SES, comorbidities, and CHD
severity to race–HEM association. Further studies are
needed to understand the mechanisms and interplay of
these factors and to develop interventions to reduce these
disparities.
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